

CINCLUS PHARMA SPONSORS A SCIENTIFIC CONFERENCE ABSTRACT HIGHLIGHTING THE SIGNIFICANT CLINICAL AND ECONOMIC COSTS OF PPI TREATMENT FAILURES IN SEVERE EROSION GERD

Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing the next-generation treatments for acid-related diseases, today announced that the company has sponsored a scientific conference abstract that is presented at ISPOR, International Society for Pharmacoeconomics and Outcomes Research, Europe 2025 conference in Glasgow, UK, on November 9-12.

The abstract titled *The Hidden Clinical and Economic Costs of PPI Treatment Failures in Severe Erosive Oesophagitis* is written by Per Svangren RPh, MSc and Dr. Paul Miller.

The abstract highlights the clinical and economic burden of persistent, unhealed severe erosive GERD (LA grade C/D) in the UK. Many patients remain unresponsive to the current standard treatment with PPIs (proton pump inhibitor), leading to significant healthcare costs and reduced quality of life. Ongoing treatment failures drive referrals, surgeries, and long-term complications. The findings in the abstract emphasize the urgent need for new therapies beyond current PPI options, as the high costs of treatment failure make investment in better treatments economically justified.

To access the abstract, please click the following link:

ISPOR - The Hidden Clinical and Economic Costs of PPI Treatment Failures in Severe Erosive Esophagitis

"This study confirms the importance of healing patients with severe erosive GERD, both from a patient and a health economic perspective. Linaprazan glurate has excellent potential to help these patients while also offering a cost-effective treatment," says Christer Ahlberg, CEO of Cinclus Pharma.

ISPOR Europe is a conference that focuses on health economics and outcomes research. This year's theme, *"Powering Value and Access Through Patient-Centered Collaboration,"* emphasizes the importance of strengthening partnerships across the healthcare ecosystem to accelerate patient-centered decision-making on healthcare value and access.

About Cinclus Pharma's drug candidate Linaprazan glurate

Cinclus Pharma's drug candidate linaprazan glurate is a next-generation of potassium competitive acid blockers (PCAB) that has an acid control inhibiting profile that enables enhanced healing and symptom relief in patients with severe forms of acid-related diseases.

The company initiated the first Phase III trial, HEEALING 1 during the third quarter 2025. The goal is to demonstrate superior healing efficacy compared with the proton pump inhibitor lansoprazole in patients with moderate to severe erosive GERD after four weeks of treatment, as well as sustained healing and symptom relief for up to eight weeks.

In the Phase II studies, healing rates of up to 93 percent were observed after four weeks of treatment in patients with moderate to severe erosive GERD, compared with only 38 percent for lansoprazole. Among patients who had previously shown only partial response to eight weeks of PPI treatment, 100 percent healing was achieved after four weeks in the most effective dose group

About Cinclus Pharma

Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. The first Phase III study commenced in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit www.cincluspharma.com.

For additional information, please contact:

Christer Ahlberg, CEO
Phone: +46 70 675 33 30
e-mail: christer.ahlberg@cincluspharma.com

Henrik Vikström, IR
Phone: +46 70 952 80 06
e-mail: henrik.vikstrom@cincluspharma.com

Attachments

Cinclus Pharma sponsors a scientific conference abstract highlighting the significant clinical and economic costs of PPI treatment failures in severe erosive GERD